Related Experiment Videos
Physiological and x-ray studies of potential antisickling agents
Summary
Two antilipoproteinemia drugs, clofibrate and gemfibrozil, show potential in inhibiting sickle cell hemoglobin (HbS) gelation. Their active metabolite, clofibric acid, binds to specific sites on hemoglobin, altering oxygen affinity.
Area of Science:
- Biochemistry
- Molecular Biology
- Hematology
Background:
- Sickle cell disease (SCD) is characterized by the polymerization of sickle hemoglobin (HbS).
- Aromatic compounds have shown potential in inhibiting HbS gelation.
- Understanding the binding sites and mechanisms of these inhibitors is crucial for therapeutic development.
Purpose of the Study:
- To investigate the antigelling activity of aromatic compounds against sickle cell hemoglobin.
- To correlate the antigelling activity with the stereochemistry of compound binding to hemoglobin.
- To discover novel therapeutic agents for sickle cell disease.
Main Methods:
- Screening of aromatic compounds for antigelling activity.
- X-ray crystallography to determine the binding sites of active compounds within hemoglobin.
- Oxygen affinity measurements to assess the effect of compounds on hemoglobin function.
Main Results:
- Two antilipoproteinemia drugs, clofibrate and gemfibrozil, exhibited significant antigelling activity.
- Crystallographic analysis revealed specific binding sites for clofibric acid (clofibrate's active metabolite) in deoxyhemoglobin A and carbon monoxide hemoglobin A.
- Clofibric acid and related compounds decreased, rather than increased, the oxygen affinity of hemoglobin, distinguishing them from other antigelling agents.
Conclusions:
- Clofibrate and gemfibrozil represent a novel class of HbS antigelling agents.
- The stereochemistry of clofibric acid binding is critical for its antigelling effect.
- These findings offer new therapeutic strategies for managing sickle cell disease by targeting HbS polymerization and oxygen transport.